NovoCure's Glioblastoma Trial Misses Primary Endpoint, Shares Down 11%
NVCR sits 44% above its 52-week low of $9.82.
Summary
NovoCure's Phase 3 TRIDENT trial for glioblastoma failed to meet its primary endpoint, showing no statistically significant improvement in overall survival. Patients initiating treatment earlier had a median overall survival of 17.7 months, barely different from 17.5 months for later initiation. This follows an 8-K filed earlier today disclosing these results. Missing a late-stage trial endpoint for a key indication is a significant setback for the company's pipeline and future revenue potential, leading to an 11% drop in premarket trading.
At the time of this announcement, NVCR was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $9.82 to $18.92. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.